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For decades, the pharmaceutical industry was 
lauded for its role in improving the health of 
the world’s population. However, the industry 
has faced significant challenges in recent years. 
Its pipeline of new products has weakened, and 
costs for research and development, sales, and 
marketing have increased. Other issues—such as 
increased scrutiny of pharmaceutical practices, 
concern over the high cost of pharmaceuticals, 
and litigation related to several high-profile 
drug safety recalls—have served to tarnish 
the industry’s reputation. This combination of 
factors has forced the industry to reassess how 
it conducts business. This article will explore a 
few of the ways pharmaceutical companies are 
attempting to operate more efficiently and work  
to repair their image and regain public trust.
There has been considerable progress on the 
front to increase transparency regarding business 
practices. In March 2008, AstraZeneca announced 
that it would begin posting online a list of all 
contributions to state and federal political 
candidates, complete with recipients’ names and 
the total amount contributed.1 Two months later, 
Eli Lilly issued a statement in support of the 
Physicians Payments Sunshine Act, legislation 
sponsored by Senators Charles Grassley (R-Iowa) 
and Herbert Kohl (D-Wisconsin) to create a 
national registry of all payments over $500 made 
to physicians by pharmaceutical companies, 
medical device, and medical supply companies. 
Lilly announced it would begin voluntarily 
reporting this information online in 2009.2 
Merck,  in September 2008, pledged to disclose 
physician payments for speaking engagements 
beginning in 2009.3
Pfizer also made significant strides to reduce 
potential conflicts of interest. In July 2008 it 
announced that the company would no longer 
directly support Continuing Medical Education 
(CME) courses offered by for-profit medical 
education and communication companies.4 
This action attempts to ensure that CME  
courses remain focused on improving clinical  
care and patient outcomes, and are not  
mistaken for promotional programs.
Given the current difficult economic environment, 
many firms are turning to mergers and layoffs 
to improve efficiency and lower operating costs. 
High-profile mergers, such as the Eli Lilly and 
ImClone merger completed in November 2008,5 
can serve to expand a company’s pipeline of future 
medications and help to re-focus their efforts 
on innovative therapies instead of relying on 
“me-too” and patent-extending reformulations 
of existing medications. Wyeth, Merck and 
several other companies have, in recent months, 
announced workforce reductions of greater than 
ten percent.6 This reduction in the workforce 
poses many questions for the future, and it is too 
early to tell if it will also impact the progress of 
research and development.
A recent survey of industry stakeholders found 
that an astounding 94% of respondents believe 
that pharmaceutical companies spend too  
much on advertising.7 Reversing this belief is 
imperative to improving the current public 
perception of the industry. The industry is 
attempting to shed this image by regulating 
itself through guidelines set forth by the 
Pharmaceutical Research and Manufacturers  
of America (PhRMA). The most recent voluntary 
guidelines on direct-to-consumer (DTC) 
advertising, issued in December 2008, call for an 
end to off-label promotion in DTC advertising, 
and ask manufacturers to define risks as clearly  
as they define benefits in commercials and  
print ads.8 While these guidelines do nothing to 
address the sheer volume of advertising aimed  
at consumers, and are merely voluntary, they  
do address some key concerns that have been 
voiced by critics.
The changes occurring in the pharmaceutical 
industry certainly show an attempt to repair an 
image that has been tarnished in recent years 
by safety recalls, criminal fines, and compliance 
failures. The industry will need to continue to 
transform itself and focus on its core mission; to 
develop novel, innovative products that improve 
the lives of patients around the world  
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